Helen Rizos Selected Research

Tumor Suppressor Protein p14ARF (p14ARF)

10/2020	Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
2/2010	Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria.
8/2009	Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.
11/2008	p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
8/2007	Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF.
7/2007	p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.
12/2006	Physical and functional interaction of the p14ARF tumor suppressor with ribosomes.
4/2005	p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners.
3/2005	Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis.
2/2003	Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Helen Rizos Research Topics

Disease

79	Melanoma (Melanoma, Malignant) 10/2022 - 04/2005
53	Neoplasms (Cancer) 10/2022 - 02/2003
8	Neoplasm Metastasis (Metastasis) 01/2019 - 12/2012
4	Uveal melanoma 10/2022 - 11/2018
4	Disease Progression 11/2020 - 07/2013
4	Nevus (Nevi) 01/2019 - 08/2009
2	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 11/2020
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 11/2008
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2012 - 06/2010
2	Dementia (Dementias) 11/2012 - 06/2010
2	Nervous System Neoplasms (Neoplasms, Nervous System) 07/2007 - 12/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 07/2007 - 12/2006
1	Residual Neoplasm 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2020
1	Fever (Fevers) 01/2019
1	Squamous Cell Carcinoma of Head and Neck 01/2019
1	Anus Neoplasms (Anal Cancer) 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Monosomy 11/2018
1	Carcinoma (Carcinomatosis) 01/2017

Drug/Important Bio-Agent (IBA)

19	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2020 - 07/2012
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2009
12	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2013
11	Immune Checkpoint InhibitorsIBA 05/2021 - 01/2015
10	Circulating Tumor DNAIBA 01/2022 - 12/2015
10	Tumor Suppressor Protein p14ARF (p14ARF)IBA 10/2020 - 02/2003
8	dabrafenibIBA 01/2019 - 07/2012
7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2013
7	Mitogen-Activated Protein KinasesIBA 01/2021 - 07/2013
7	Pharmaceutical PreparationsIBA 01/2021 - 12/2012
7	trametinibIBA 01/2020 - 07/2013
6	Phosphotransferases (Kinase)IBA 01/2020 - 01/2013
6	VemurafenibIBA 12/2015 - 12/2012
5	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2011 - 10/2008
4	Proto-Oncogene Proteins B-rafIBA 08/2015 - 07/2012
3	Biological ProductsIBA 10/2022 - 01/2013
3	Cell-Free Nucleic AcidsIBA 11/2020 - 02/2019
3	Small Interfering RNA (siRNA)IBA 11/2020 - 11/2008
3	GSK1210151AIBA 10/2020 - 11/2014
3	CytokinesIBA 01/2019 - 11/2014
3	Messenger RNA (mRNA)IBA 11/2012 - 11/2008
2	Histocompatibility Antigens Class IIBA 06/2021 - 11/2020
2	Programmed Cell Death 1 ReceptorIBA 05/2021 - 01/2018
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021 - 02/2014
2	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 11/2014
2	IpilimumabIBA 01/2018 - 12/2015
2	AntibodiesIBA 01/2018 - 06/2010
2	CateninsIBA 10/2017 - 01/2014
2	Transcription Factors (Transcription Factor)IBA 11/2014 - 04/2014
2	Glucose (Dextrose)FDA LinkGeneric 04/2014 - 02/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2013 - 11/2005
2	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 08/2009 - 07/2007
1	Protein Kinase InhibitorsIBA 10/2022
1	LigandsIBA 10/2022
1	InflammasomesIBA 01/2022
1	Temozolomide (Temodar)FDA LinkGeneric 01/2022
1	Chloroquine (Aralen)FDA LinkGeneric 01/2022
1	Peptides (Polypeptides)IBA 06/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2021
1	HLA-DR Antigens (HLA-DR)IBA 05/2021
1	Protein Kinase CIBA 04/2021
1	AntigensIBA 11/2020
1	antiglomerular basement membrane antibodyIBA 11/2020
1	S63845IBA 10/2020
1	Apoptosis Regulatory ProteinsIBA 10/2020
1	Immune Checkpoint ProteinsIBA 01/2020
1	Nucleic AcidsIBA 02/2019
1	Alanine (L-Alanine)FDA Link 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Formaldehyde (Formol)FDA Link 01/2019
1	ParaffinIBA 01/2019
1	Serine (L-Serine)FDA Link 01/2019
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	Dual Specificity Phosphatase 6IBA 01/2019
1	Peptide Initiation Factors (Initiation Factor)IBA 11/2018
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2018
1	RNA Splicing FactorsIBA 11/2018
1	Histone Deacetylase InhibitorsIBA 01/2018
1	CaspasesIBA 01/2018
1	encorafenibIBA 01/2018
1	Tumor Biomarkers (Tumor Markers)IBA 01/2018
1	InterferonsIBA 01/2018
1	PanobinostatIBA 01/2018
1	Therapeutic UsesIBA 06/2017
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2017
1	Blood Proteins (Serum Proteins)IBA 01/2017
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2017
1	pembrolizumabIBA 12/2015
1	NivolumabIBA 12/2015
1	tubulin-specific chaperone CIBA 08/2015
1	JNK Mitogen-Activated Protein KinasesIBA 08/2015
1	talimogene laherparepvecIBA 01/2015

Therapy/Procedure

30	Therapeutics 01/2022 - 07/2012
15	Immunotherapy 10/2022 - 01/2014
5	Drug Therapy (Chemotherapy) 01/2022 - 11/2008
2	RNAi Therapeutics 11/2021 - 11/2020
2	Neoadjuvant Therapy 01/2019 - 01/2019
1	Radiotherapy 01/2020
1	Oncolytic Virotherapy 01/2015